The use of Jelonet dressings in the treatment of drug toxicity in autologous stem cell transplantation in children. Clinical case presentation-Reference-Cited by-同舟云学术

The use of Jelonet dressings in the treatment of drug toxicity in autologous stem cell transplantation in children. Clinical case presentation

Published:2021-10-19 Issue:3 Volume:8 Page:97-101
ISSN:2413-5496
Container-title:Russian Journal of Pediatric Hematology and Oncology
language:
Short-container-title:Ross. ž. det. gematol. onkol.

Author:

Aliev T. Z.¹^ORCID,Belysheva T. S.¹^ORCID,Sergeenko K. A.²^ORCID,Machneva E. B.³^ORCID,Sidorova N. V.¹^ORCID,Valiev T. T.¹^ORCID,Kostareva I. O.⁴^ORCID,Kirgizov K. I.¹^ORCID

Affiliation:

1. N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

2. Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia

3. N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

4. N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

Abstract

One of the complications arising at the stage of hematopoietic stem cell transplantation (HSCT) is skin lesions. This complication is quite common and represents an important diagnostic and therapeutic problem. The main cause of skin lesions in HSCT is drug toxicity, but also infectious lesions. Each of the complications can manifest itself in varying degrees, as well as be combined with others, having a significant negative effect on the patient’s condition, in severe cases posing a threat to the patient’s life. This paper presents a clinical case of a patient with treosulfan toxicoderma who was treated with JELONET dressings.

Publisher

OOO Grafika

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference10 articles.

1. Rosman I.S., Lloyd B.M., Hayashi R.J., Bayliss S.J. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol 2008;58(4):575–8. doi: 10.1016/j.jaad.2007.12.037.

2. The EBMT Handbook. Hematopoietic Stem Cell Transplantation and Cellular Therapies. Eds.: Carreras E., Dufour C., Mohty M., Kröger N. Springer, 2019. 688 r. doi: 10.1007/978-3-030-02278-5

3. Mays S.R., Kunishige J.H., Truong E., Kontoyiannis D.P., Hymes S.R. Approach to the morbilliform eruption in the hematopoietic transplant patient. Semin Cutan Med Surg 2007;26(3):155–62. doi: 10.1016/j.sder.2007.09.004.

4. Strocchio L., Zecca M., Comoli P., Mina T., Giorgiani G., Giraldi E., Vinti L., Merli P., Regazzi M., Locatelli F. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. Br J Haematol 2015;169(5):726–36. doi: 10.1111/bjh.13352.

5. Bolognia J.L., Cooper D.L., Glusac E.J. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008;59(3):524–9. doi: 10.1016/j.jaad.2008.05.018.